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Abstract
 
The low frequency of self-peptide–specific T cells in the human preimmune repertoire has so
far precluded their direct evaluation. Here, we report an unexpected high frequency of T cells
specific for the self-antigen Melan-A/MART-1 in CD8 single–positive thymocytes from hu-
man histocompatibility leukocyte antigen-A2 healthy individuals, which is maintained in the
peripheral blood of newborns and adults. Postthymic replicative history of Melan-A/MART-1–
specific CD8 T cells was independently assessed by quantifying T cell receptor excision circles
and telomere length ex vivo. We provide direct evidence that the large T cell pool specific for
the self-antigen Melan-A/MART-1 is mostly generated by thymic output of a high number of
precursors. This represents the only known naive self-peptide–specific T cell repertoire directly
accessible in humans.
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Introduction
 
The composition of self-peptide ligands present in the
thymus plays a critical role in shaping the preimmune T
cell repertoire (1, 2). Immature thymocytes expressing
TCRs with low affinity for self-peptide/MHC survive
and undergo further maturation (positive selection).
Overtly autoreactive T cells are deleted by induction of
programmed cell death (negative selection). Thereby, ma-
ture thymocytes with low affinity to self-peptide/MHC
migrate to the periphery, founding a highly diverse T cell
repertoire (3, 4). Additionally, self-peptide/MHC ligands
deliver survival signals to naive T cells for their persistence
in the periphery (5, 6). The recognition of self-peptides by
T cells through the TCR has exquisite specificity as dem-
onstrated by the drastic effects of single amino acid substi-
tutions (7). However, the high degree of peptide cross-
reactivity built in the T cell repertoire ensures recognition
of virtually any presentable peptide. Synthetic peptide li-
braries contributed to the identification of multiple ligands
that stimulate the same T cell clone without necessarily dis-
playing sequence homology (8). It has been estimated that
the frequency of individual epitope-specific naive T cells
ranges around 1–5 
 

 
 10
 

 
5
 
 (9), which is below the limit of
direct detection with currently available assays. TCR-trans-
genic approaches provide model systems for monitoring
the selection process and in vivo fate of naive antigen-spe-
cific T cells (10). In humans, however, the low frequency
of self-peptide–specific T cells in the preimmune repertoire
has so far precluded their precise investigation.
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High Frequency of Precursors Specific for Melan-A
 
The melanocyte differentiation antigen Melan-A/MART-1
(Melan-A)
 
*
 
 is a self-protein of unknown function that is
expressed by melanocytes and the majority of malignant
melanoma cells, but not by other tissues (11, 12). HLA-
A2–restricted Melan-A–specific CD8 T cells have been
shown to primarily recognize the Melan-A 26–35 and 27–35
peptides (13, 14). Using HLA-A2 multimers synthesized
around the Melan-A 26–35 A27L peptide analogue, we
were able to identify Melan-A–specific T cells ex vivo in
both tumor-infiltrated LNs and circulating lymphocytes of
melanoma patients, as well as healthy individuals (15, 16).
In the latter, Melan-A–specific T cells are phenotypically
naive (CCR7
 

 
 CD45RA
 
high
 
 CD45RO
 
–
 
 CD28
 

 
), and sur-
prisingly comprise 
 

 
10
 

 
3
 
 of circulating CD8 T cells (17–19).
This frequency is at least 10
 
2
 
 times higher than the one cur-
rently estimated for naive antigen-specific lymphocyte pre-
cursors, and is comparable to that of epitope-specific mem-
ory CD8 T cells. This raises the question of how this
unexpected large T cell pool is established and maintained.
Obviously, the surface markers used in previous studies
may not reliably reflect the functional state of Melan-A–
specific T cells. In this regard, it has been shown that naive
T cells may undergo expansion without phenotype change
(20), or revert to a naive state after transient homeosta-
sis-driven activation (21–23). Furthermore, memory T
cells may revert to a naive phenotype (24). Alternatively,
Melan-A–specific T cells may represent true naive lympho-
cytes due to increased life span in the periphery or in-
creased thymic production.
In this study, we identified the mechanism for the exist-
ence of a large naive repertoire of T cells specific for the
self-antigen Melan-A. Using MHC/peptide multimers, we
enumerated Melan-A–specific T cells in the thymus and
periphery of newborns and adults. To directly define the
contribution of thymic production to this large self-specific
T cell pool, we combined A2/Melan-A multimer labeling
with measurement of postthymic replicative history by
quantification of T cell receptor excision circles (TRECs)
(25–27). During thymus development, formation of a pro-
ductive TCR-
 

 
 rearrangement requires deletion of the
TCR-
 

 
 locus that is located within the TCR-
 

 
 locus. Be-
fore TCR-
 

 
 rearrangement, two TCR-
 

 
–deleting ele-
ments, 
 

 
Rec and 
 

 
J
 

 
, preferentially rearrange to each
other, thereby deleting the TCR-
 

 
 locus. The TCR-
 

 
 de-
letion product remains present as an extrachromosomal cir-
cle, the so-called signal joint TREC (28). TRECs are epi-
somal excision circles that are stable, do not duplicate
during mitosis, and consequently are diluted during cell di-
vision. We also measured the average length of telomere
repeat sequences in Melan-A–specific T cells by quantita-
tive fluorescence in situ hybridization and flow cytometry
(flow FISH [29]), as an independent marker of their repli-
cative history in vivo. Telomeres are specialized structures
at the end of eukaryotic chromosomes whose length de-
creases with age and population doublings in vitro. Despite
transient telomerase activity, the telomere length of mem-
ory CD4 and CD8 T lymphocytes is significantly shorter
than that of naive T cells (30, 31). For the first time, deter-
mination of TRECs and telomere length in antigen-spe-
cific CD8 T cells ex vivo provide direct evidence that a
high frequency of thymic precursors is the predominant
mechanism shaping the Melan-A–specific T cell preim-
mune repertoire
 
.
 
 Implications for the presence of Melan-A
cross-reactive ligands during thymic selection are discussed.
 
Materials and Methods
 
Tissues and Cells. 
 
Peripheral blood from 40 healthy donors
(HD) that were 19–82-yr-old was collected at the Blood Trans-
fusion Center (Lausanne, Switzerland). Three melanoma patients
with stage III/IV disease who had undergone therapeutic tumor
resection were selected for this study. After informed consent was
obtained, tumor-infiltrated LNs (TILNs) were collected from pa-
tient LAU 465, and from patients LAU 359 and LAU 362. PBMCs
from all patients were obtained at the time of surgery. Cord blood
(CB) from 22 newborns and pediatric thymus tissue from 20 chil-
dren who were 0–12-yr-old and had undergone corrective car-
diac surgery, were collected at the University Hospital of Ghent
(Ghent, Belgium), adhering to the guidelines of the Medical Eth-
ical Commission of the hospital. Lymphocytes were prepared and
cryopreserved as previously described (17). When indicated, lym-
phocytes were selected on the basis of HLA-A2 expression.
 
MHC/Peptide Multimers and mAbs. 
 
Synthesis of PE- and
APC-labeled HLA-A2/peptide multimers was performed as pre-
viously described (15, 32). The peptides used were Melan-A
 
26–35
 
A27L (ELAGIGILTV), influenza matrix Flu-MA
 
58–66
 
 (GILG-
FVFTL), CEA
 
694–702
 
 (GVLVGVALI), gp100
 
209–218
 
 T210M (IM-
DQVPFSV) (33), tyrosinase
 
368–376
 
 (YMDGTMSQV), MAGE-
4
 
254–262
 
 (GVIDGRIHMV), MAGE-10
 
130–139
 
, and NY-ESO-
1
 
157–165
 
 C165A (SLLMWITQA) (34). Because of the unstable
binding of the Melan-A
 
26–35
 
 natural peptide (EAAGIGILTV) to
HLA-A2 (35), multimer synthesis around this peptide was per-
formed using HLA-A2 molecules incorporating an unpaired cys-
teine residue at the COOH terminus, which allows site-specific
biotinylation at 4
 

 
C (36). mAbs were from Becton Dickinson,
except anti–CD45RO-FITC (Dako), anti–CD28-FITC (Immu-
notech), anti–perforin-FITC (Ancell), goat anti–rat IgG FITC
(Southern Biotechnology Associates, Inc.), anti–CD8-ECD (Coulter
Corp.), and goat anti–rat IgG APC (Caltag). Anti-CCR7 rat IgG
mAb 3D12 and anti-2B4 rat IgG mAb were provided by Drs. M.
Lipp and R. Forster (Max Delbrück Institute, Berlin, Germany),
and Dr. M. Colonna (Basel Institute for Immunology, Basel,
Switzerland), respectively.
 
FACS
 
®
 
. 
 
CD8 T lymphocytes were positively enriched
from PBMCs and CB lymphocytes using CD8 microbeads
(Miltenyi Biotec), whereas CD8 single positive (SP) thymocytes
were negatively enriched using CD4 microbeads. Cells were
stained with PE- and/or APC-labeled multimers for 1 h at room
temperature in PBS, 0.2% BSA, 50 
 
	
 
M EDTA, and then incu-
bated with appropriate mAbs for 20 min at 4
 

 
C. Cells were ei-
ther immediately analyzed on a FACSCalibur
 
®
 
 or sorted into de-
fined populations on a FACSVantage
 
®
 
 SE, using CellQuest
software (Becton Dickinson). To maximize purification effi-
ciency, the flow speed used during cell sorting corresponded to
 

 
2 
 

 
 10
 
3
 
 cells per second. Purification of 5 
 

 
 10
 
3
 

 
2 
 

 
 10
 
5
 
*
 
Abbreviations used in this paper:
 
 CB, cord blood; DP, double positive; flow
FISH, fluorescence in situ hybridization and flow cytometry; HD, healthy
donor; Melan-A, Melan-A/MART-1; SP, single positive; TILN, tumor
infiltrated lymph node; TREC, T cell receptor excision circles.
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A2/Melan-A
 

 
 or A2/Flu-MA
 

 
 cells required 5–12 h sorting.
Immediate reanalysis of the isolated populations revealed 
 


 
98%
purification efficiency.
 
Quantitative PCR of TRECs. 
 
Quantification of signal joint
(sj) TRECs in sorted CD8 T cells was performed by real time
quantitative PCR with the 5
 

 
 nuclease (TaqMan) assay and an
ABI7700 system (PerkinElmer). As previously described (25),
cells were lysed in 100 mg/liter proteinase K (Roche Molecular
Diagnostics) for 2 h at 56
 

 
C, and then for 15 min at 95
 

 
C. Each
PCR reaction was performed in a 25-
 
	
 
l solution containing 5 
 
	
 
l
of cell lysates, 12.5 
 
	
 
l of TaqMan
 
®
 
 Universal Master Mix, in-
cluding AmpliTaq Gold (Applied Biosystems), 500 nM of each
primer (sj-5
 

 
 forward: CAC ATC CCT TTC AAC CAT GCT;
sj-3
 

 
 reverse: GCC AGC TGC AGG GTT TAG G), and 125
nM probe (FAM-ACA CCT CTG GTT TTT GTA AAG GTG
CCC ACT-TAMRA) in a final volume of 25 
 
	
 
l. The PCR con-
ditions consisted of 1 cycle of 2 min at 50
 

 
C and 1 cycle of 10
min at 95
 

 
C, followed by 40 cycles of 30 s at 95
 

 
C and 1 min at
65
 

 
C. 10-fold serial dilutions ranging from 10
 
7
 
 to 10
 
1
 
 copies of sj
internal standard provided by Dr. Daniel Douek (Vaccine Re-
search Center, National Institute of Allergy and Infectious Dis-
eases, Bethesda, MD), were tested in quadruplicates in each PCR
experiment. A standard curve with a linear range across 7 logs
DNA concentration was created, which calculated the number of
TRECs in a given cell population. Thus, the lowest limit of
quantification was considered to be 10 copies of the target se-
quence. In all PCR assays, the correlation coefficient of the stan-
dard curve was 
 

 
0.997, whereas the slope varied between –3.52
and –3.67. TREC levels in total CD8 T cells and CCR7
 

 
/–
 
CD45RA
 
high/low
 
 populations revealed comparable results when
using 5 
 

 
 10
 
3
 
–10
 
5
 
 cells (linear regression analysis, 
 
P
 
 
 
 
 
0.001; un-
published data). For each quantification, at least two independent
cell sorting were performed and TREC levels were quantified by
PCR in eight or more replicates.
 
Flow FISH. 
 
CD8 T cells were sorted ex vivo into 0.6–2 
 

 
10
 
5
 
 A2/Melan-A
 

 
, A2/Flu-MA
 

 
, naive CCR7
 

 
CD45RA
 
high
 
,
and memory–effector non-CCR7
 

 
CD45RA
 
high
 
 T cells. The av-
erage length of telomere repeats at chromosome ends in individ-
ual cells, was measured by quantitative flow FISH as previously
described (29, 30). FITC-labeled fluorescent calibration beads
(Quantum TM-24 Premixed; Bangs Laboratories Inc.) were used
to convert telomere fluorescence data to molecules of equivalent
soluble fluorescence (MESF) units. The following equation was
performed to estimate the telomere length in basepair from telo-
mere fluorescence in MESF units (bp 
 

 
 MESF 
 

 
 0.495; [29]).
 
Cytolytic Activity. 
 
CD8 T cells were sorted ex vivo into 1–2 
 

 
10
 
3
 
 A2/Melan-A
 

 
, A2/Flu-MA
 

 
, and A2/multimer
 

 
 cells on a
FACSVantage
 
®
 
 SE, and then stimulated with 1 
 
	
 
g/ml PHA-L,
150 U/ml IL-2, 10 ng/ml IL-7, and 10
 
6
 
/ml allogeneic irradiated
PBMCs. After 2 wk, the populations were 
 


 
95% pure as assessed
by multimer staining. Cells were tested for their lytic activity
against peptide-pulsed HLA-A2
 

 
 TAP-deficient T2 cells, and
melanoma cells Na 8 (HLA-A2
 

 
, Melan-A
 

 
) or Me 290 (HLA-
A2
 

 
, Melan-A
 

 
) in 4 h 
 
51
 
Chromium release assays. The percent-
age of specific lysis was calculated as previously described (17).
Results
 
High Frequency of Circulating Melan-A–specific CD8 T Cells
in Healthy HLA-A2 Individuals. 
 
We first determined the
frequency of HLA-A2
 

 
 adult individuals with a number of
circulating Melan-A–specific CD8 T cells detectable by
staining with A2/Melan-A multimers. Staining of PBMCs
from HLA-A2
 
–
 
 individuals with these multimers has al-
lowed the definition of a lower detection limit of 1 per
2,500 CD8 T cells (cut off 
 

 
 mean 
 

 
 3 SD 
 

 
 0.01% 
 

 
 3 
 

 
0.01% 
 

 
 0.04%) under the experimental conditions
used (17). Significant numbers of A2/Melan-A
 

 
 cells were
detected in 23 out of 31 (74%) HLA-A2
 

 
 individuals
(mean 
 

 
 SD, 0.07% 
 

 
 0.04% of CD8 T cells). In con-
trast, CD8 T cells specific for other known self-peptides
(CEA
 
694–702
 
, gp100
 
208–218
 
, tyrosinase
 
368–376
 
, MAGE-4
 
130–139
 
,
MAGE-10
 
254–262
 
, and NY-ESO-1
 
157–165
 
) were not detect-
able. The data obtained in a positive individual (HD 009)
are shown in Fig. 1 a. In this study, we used HLA-A2
multimers that were synthesized around the Melan-A
Figure 1. High frequency of phenotypically naive circulating Melan-A–
specific CD8 T Cells in HLA-A2 healthy individuals. (a) Purified CD8 T
cells from individual HD 009 were stained with anti-CD3, anti-CD8
mAbs, and HLA-A2 multimers synthesized around peptides derived from
self-proteins (Melan-A26–35 A27L analogue, CEA694–702, gp-100209–217
T210M analogue, tyrosinase368–376, MAGE-4130–139, MAGE-10254–262, or
NY-ESO-1157–165 C165A analogue) and influenza matrix protein (Flu-
MA58–66). The sequence of each peptide is shown on the top of the corre-
sponding dot plot. Figures in upper right quadrants are the percentages of
multimer cells in gated CD3CD8 cells. (b) Purified CD8 T cells from
individual HD 009 were stained here with multimers synthesized around
the Melan-A26–35 natural peptide. (c) Purified Melan-A–specific CD8 T
cells from individual HD 009, which had been expanded in vitro were
stained with an anti-CD8 mAb, and multimers synthesized around the
A27L Melan-A26–35 A27L analogue (left), the Melan-A26–35 natural pep-
tide (middle), and the irrelevant influenza matrix58–66 peptide (right). Dot
plots are representative examples for six Melan-A–specific populations
derived from PBMCs of adults and newborns, and from thymus. (d) Puri-
fied CD8 T cells from individual HD 009 were stained with A2/Melan-A
multimers and a set of mAbs as indicated. Gated A2/Melan-A cells are
painted in gray and negative controls are in white.
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A27L analogue peptide. The interchangeability between
Melan-A A2/analogue (ELAGIGILTV) and A2/natural
(EAAGIGILTV) peptide multimers has been previously
demonstrated using tumor-specific CD8 T cells derived
from melanoma patients (15). To confirm this finding in
healthy individuals, we determined the frequency of circu-
lating Melan-A–specific T cells from HD 009 that were
detected with Melan-A A2/natural peptide multimers. As
shown in Fig. 1 b, the frequency was similar to that ob-
tained with Melan-A A2/analogue peptide multimers.
Furthermore, we found that A2/Melan-A
 

 
 populations,
which had been expanded in vitro, were efficiently and
specifically stained with multimers synthesized around ei-
ther peptide (mean, 97%; SD, 6%, Fig. 1 c). Because of the
unstable binding of the natural peptide to HLA-A2 (35),
multimers synthesized around the A27L analogue peptide
were used in further studies.
Previous reports have shown that circulating Melan-A–
specific CD8 T cells from healthy individuals express the
CD45RA, CCR7, and CD28 surface markers (17–19). In
agreement with these results, we observed that A2/
Melan-A
 

 
 cells were homogeneously CD45RA
 
high
 
 CCR7
 

 
CD28
 

 
 (mean, 95%; SD, 4%) in all individuals. Further
analysis revealed that A2/Melan-A
 

 
 cells were also CD27
 

 
CD45RO
 

 
 CD56
 

 
 CD57
 

 
 CD62L
 

 
 2B4
 

 
 perforin
 

 
, and
expressed neither the activation markers CD25, CD69, and
HLA-DR, nor the proliferation marker Ki67 (Fig. 1 d). Al-
together, these results indicate that a relatively high fre-
quency of phenotypically naive Melan-A–specific T cells is
detectable in the peripheral blood of the majority of
healthy HLA-A2
 

 
 individuals. In marked contrast, circulat-
ing A2/Flu-MA
 

 
 cells, which we detected by multimer
staining in 30 out of 31 (97%) HLA-A2
 

 
 individuals
(mean 
 

 
 SD, 0.14% 
 

 
 0.16% of CD8 T cells; unpublished
data), exhibit a memory CD45RA
 
low
 
 phenotype (84% 
 

 
17%; unpublished data).
 
TREC Levels in CD8 T Cell Subsets. 
 
As a first ap-
proach to establish that circulating Melan-A–specific CD8
T cells are indeed naive, we determined TREC levels in
naive versus memory/effector CD8 T cells. To this end,
we sorted four subsets of circulating CD8 T cells on the
basis of CCR7 and CD45RA expression (Fig. 2 a). This
cell surface marker combination has recently been shown
to effectively separate naive and memory/effector lym-
phocytes (37). TREC levels were measured in each CD8
T cell subset by quantitative PCR. In the four individ-
uals tested, regardless of the age, TREC levels in the
CCR7
 

 
CD45RA
 
high
 
 subset were approximately one or-
der of magnitude higher than in the three other subsets
(Fig. 2 b). To validate these data, we estimated the average
TREC levels in the whole CD8 T cell population by add-
ing the TREC levels obtained for each T cell subset, and
multiplying by their relative frequency (Fig. 2 b, reconsti-
tuted CD8
 

 
). In all cases, these reconstituted values were
comparable with the PCR-quantified TREC levels mea-
sured directly in the unfractionated autologous CD8 T
cell population.
 
Melan-A–specific CD8 T Cells in Healthy Individuals Retain
High TREC Levels and Long Telomeres. 
 
The results de-
scribed above suggest that determination of TREC levels
could provide useful information on the postthymic repli-
cative history of circulating antigen-specific CD8 T cell
populations. Therefore, we combined A2/peptide multi-
mer-based cell separation and measurement of TRECs.
Purified CD8 T cells from four HLA-A2 individuals were
sorted into A2/Melan-A
 

 
 (0.05–0.10% of CD8 T cells)
and A2/Flu-MA
 

 
 (0.05–0.21%) populations (Fig. 3 a). In
parallel, naive (CCR7
 

 
CD45RA
 
high
 
) and memory/effector
(non-CCR7
 

 
CD45RA
 
high
 
) CD8 T cell subsets were also
sorted (Fig. 3 b). TREC levels were determined in each
population, thus allowing a direct comparison between an-
tigen-specific, naive, and memory/effector CD8 T cell
populations derived from the same individual’s blood sam-
ple. This analysis revealed relatively high levels of TRECs
in A2/Melan-A
 

 
 cells from all four individuals. TREC
levels represented 47–69% (mean, 57%; SD, 9%) of those
found in the autologous-naive CD8 T cells (Fig. 3 c), sug-
gesting that on average, Melan-A–specific T cells have
completed only one additional cell division. In marked
contrast, TREC levels were below detection in purified
A2/Flu-MA
 

 
 cells (Fig. 3 c), and thus were similar to the
levels observed in memory/effector CD8 T cells. It is thus
apparent that on average, A2/Flu-MA
 

 
 cells completed
seven or more rounds of division as compared with autolo-
gous-naive and Melan-A–specific T cells.
As an independent approach, the average length of telo-
mere repeats was measured in the four populations de-
scribed above by flow FISH (29). Telomere length is
Figure 2. CCR7CD45RAhigh
CD8 T cells contain high levels of
TRECs ex vivo. (a) Purified CD8 T
cells were stained with anti-CD3,
anti-CD8, anti-CCR7, and anti-
CD45RA mAbs. Gated CD3CD8
cells were sorted into four subsets on
the basis of CCR7 and CD45RA
expression. (b) Real time PCR
quantification of TRECs was per-
formed in whole CD8 T cells
(CD8) and in CCR7/–CD45RAhigh/low sorted subsets obtained from four individuals (HD 008, 009, 019, and 025). Figures in the left of each bar are
the percentage of the corresponding subsets within whole CD8 T cells. TREC levels in whole CD8 T cells were also calculated by adding the TREC
levels obtained for each CD8 T cell subset and multiplying by their relative frequency (reconstituted CD8).
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an indicator of the replicative history of cells because
lymphocytes gradually shorten their telomeres upon suc-
cessive cell divisions (30). In agreement with the TREC
data, both the naive and A2/Melan-A
 
 CD8 T cell popu-
lations displayed the brightest telomere fluorescence with a
mean value corresponding to a telomere length of 8.1 and
8.0 kb, respectively. Measurement of the replicative history
by assessing telomere length does not allow the detection of
slight differences in the number of cell divisions between
two populations. Thus, TREC dilution by 50% in the
Melan-A–specific T cells compared with the autologous-
naive CD8 T cells is not reflected by detectable changes in
telomere length. In contrast, both the memory/effector
and A2/Flu-MA CD8 T cell populations showed signifi-
cantly reduced telomere fluorescence corresponding to a
telomere loss of 1.6 kb (Fig. 3 d). The lack of TREC di-
lution and telomere shortening observed in Melan-A–spe-
cific CD8 T cells from healthy individuals provides direct
evidence that they are naive.
Memory/Effector Melan-A–specific CD8 T Cells Display
Reduced TREC Levels and Shortened Telomeres. We and
other groups have demonstrated that in contrast to healthy
individuals (Fig. 1 d), Melan-A specific–CD8 T cells may
exhibit a memory/effector phenotype in patients with met-
astatic melanoma (15, 16, 18). To verify the relationship
between phenotype shift and peripheral expansion in vivo,
we determined the replicative history of Melan-A–specific
T cells taken from three patients. In patient LAU 465
Melan-A–specific T cells were identified in PBMCs and
TILNs (0.55% and 13% of CD8 T cells, respectively).
From these cells, 84% and 100%, respectively, exhibited a
memory/effector phenotype (Fig. 4 a). In contrast to our
findings in healthy individuals, TRECs in A2/Melan-A
PBMCs and TILNs were not detectable (Fig. 4 b). Identi-
cal observations were made with TILNs obtained from
melanoma patients LAU 359 and LAU 362. Elevated fre-
quencies of A2/Melan-A cells (2.1% and 0.7% of CD8 T
cells, respectively) were identified by multimer staining.
Again, the vast majority (
95%) of these cells exhibited a
memory/effector phenotype and did not contain detectable
levels of TRECs (unpublished data). In line with these ob-
servations, the mean relative telomere length of sorted A2/
Melan-A TILNs from patient LAU 465 was comparable
to that measured in circulating memory/effector autolo-
gous CD8 T cells (Fig. 4 d, corresponding to 6.9-kb telo-
mere length). This represents a telomere shortening of 2.4
kb with respect to autologous naive CD8 T cells, indicat-
ing extensive proliferation in vivo.
High Frequency of Melan-A–specific CD8 T Cells in New-
borns. We next investigated whether the high frequency
of circulating Melan-A–specific CD8 T cells is already de-
tectable in newborns. For this purpose, we stained HLA-
Figure 3. Melan-A–specific CD8 T cells in healthy
individuals retain high TREC levels and long telo-
meres. (a) Purified CD8 T cells from HLA-A2 individ-
uals were stained with anti-CD3 and anti-CD8 mAbs,
together with PE-labeled A2/Melan-A and APC-
labeled A2/Flu-MA multimers. Gated CD3CD8
cells were sorted into A2/Melan-A and A2/Flu-MA
subsets. (b) Purified CD8 T cells were stained with
anti-CD3, anti-CD8, anti-CCR7, and anti-CD45RA
mAbs. Gated CD3CD8 cells were sorted into naive
CCR7CD45RAhigh and memory/effector non-
CCR7CD45RAhigh subsets. (c) Real time PCR
quantification of TRECs was performed in whole
CD8 T cells, in sorted naive and memory/effector sub-
sets, and in sorted Melan-A and influenza-specific T
cells (*, not detectable; ND, not done). Figures in the
left of each bar are the percentage of the corresponding
subsets in whole CD8 T cells. (d) Telomere fluorescence analysis was performed in sorted naive and memory/effector subsets, and Melan-A and influ-
enza-specific CD8 T cells were obtained from individual HD 009. The telomere fluorescence was calculated by subtracting the mean background fluo-
rescence from the mean fluorescence obtained with the telomere probe and is expressed in kilobase, as described in the Materials and Methods section.
Figure 4. Memory/effector
Melan-A–specific CD8 T cells
display reduced TREC levels
and shortened telomeres. (a) Pu-
rified CD8 T cells were obtained
from PBMCs (top) and TILNs
(bottom) of melanoma patient
LAU 465. In the left panels, lym-
phocytes were stained with anti-
CD3, anti-CD8, anti-CCR7,
and anti-CD45RA mAbs, and
dot plots are shown for gated
CD3CD8 cells. In the right
panels, lymphocytes were stained
with anti-CCR7, anti-CD45RA
mAbs, and A2/Melan-A multi-
mers, and dot plots are shown
for gated A2/Melan-A cells. (b)
Real time PCR quantification of
TRECs was performed in whole
CD8 T cells, in sorted naive and
memory/effector CD8 T cells
from PBMCs, and in sorted
Melan-A–specific T cells from both PBMCs and TILNs (*, not detectable).
Figures in the left of each bar are the percentage of the corresponding sub-
sets in CD8 T cells. (c) Telomere fluorescence analysis was performed in
sorted naive and memory/effector CD8 T cells from PBMCs, and
Melan-A–specific CD8 T cells from TILNs. Telomere fluorescence
was calculated as in Fig. 3 d, and is expressed in kilobase (see Materials
and Methods).
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A2 CB lymphocytes with A2/Melan-A multimers. The
lower limit of detection was 0.04% of CD8 T cells, as de-
termined by A2/Melan-A multimer staining on 11 HLA-
A2 CB lymphocyte samples (cut off  mean  3 SD 
0.01%  3  0.01%; unpublished data). Significant num-
bers of A2/Melan-A cells in CB were detected in 9 out of
11 (82%) HLA-A2 newborns (Fig. 5 a, mean  SD,
0.10%  0.04% of CD8 T cells). In contrast, A2/Flu-MA
cells were not detected in CB (Fig. 5 b, 0.01%). A2/
Melan-A CB cells were CD45RAhigh (mean  SD,
94%  4%) and CCR7 (96%  4%) in 7 out of 7 indi-
viduals (Fig. 5 c, shown representatively as CB 15). In line
with a naive phenotype, A2/Melan-A cells from CB 15
contained high levels of TRECs (Fig. 5 d). As compared
with the autologous CD8 T cell pool, Melan-A–specific T
cells contained 74% of TRECs, indicating that on average
they had completed less than one cell division. Thus, the
postthymic replicative history of Melan-A–specific T cells
is similar in newborns and adults, consistent with the possi-
bility that these cells represent recent thymic emigrants.
High Frequency of Melan-A–specific CD8 SP Thymocytes.
To directly investigate the origin of the Melan-A–specific
CD8 T cell repertoire, we performed multimer staining of
lymphocytes derived from human thymus. Double positive
(DP) thymocytes form the vast majority of cells found in
the thymus. They express low levels of / TCR and are
programmed to die within 3 to 4 d unless rescued by a
TCR signal. 1–5% of the DP cells survive, increase TCR
expression, and mature to CD4 and CD8 SP cells. Cell sur-
face expression of TCR may allow direct identification of
antigen-specific cells in both the DP and SP stages of T cell
development by staining with A2/peptide multimers.
However, neither A2/Melan-A nor A2/Flu-MA cells
were detected in the pool of DP thymocytes (0.01%; un-
published data). We further investigated the presence of
antigen-specific cells in the pool of CD8 SP thymocytes.
Staining of CD4-depleted thymocytes from nine HLA-A2
individuals with A2/Melan-A multimers revealed a lower
limit of detection of 0.04% of CD8 SP cells (cut off 
mean  3 SD  0.01%  3  0.01%, unpublished data).
Similar analysis with HLA-A2 thymocytes revealed that
significant numbers of A2/Melan-A CD8 SP cells were
detectable in six out of nine (67%) individuals (Fig. 5 e,
mean  SD, 0.04%  0.01% of CD8 T cells). As expected,
A2/Melan-A cells were not detectable in CD4 SP cells
(0.01%; unpublished data). Furthermore, A2/Flu-MA
cells were not detected in the thymus (0.01% of DP,
CD4 SP, and CD8 SP cells; Fig. 5 f, and unpublished data).
Altogether, our results indicate that a high frequency of
Melan-A–, but not influenza-specific CD8 SP precursors
are generated in the human thymus.
Functional Potential of Melan-A–specific CD8 SP Thy-
mocytes. We assessed the functional potential of Melan-
A–specific CD8 T cells sorted from thymocytes of patient
02. After mitogen-driven expansion in vitro, the A2/
Melan-A population exhibited an activated pheno-
type (CCR7 CD45RAlow CD45RO CD27int CD28
CD62L CD69int HLA-DR, unpublished data). As pre-
sented in Fig. 6 a, thymus-derived A2/Melan-A cells spe-
cifically lysed T2 cells in the presence of the Melan-A26–35
natural (EAAGIGILTV) or the analogue (ELAGIGILTV)
peptide, whereas no lysis was noticed in the presence of the
irrelevant influenza matrix58–66 (GILGFVFTL) peptide.
Furthermore, peptide titration curves confirmed the fine
specificity of Melan-A peptide recognition observed in
previous studies (15, 35). Thymus-derived A2/Melan-A
cells also exhibited a high lytic activity against the HLA-
A2 Melan-A Me 290 tumor cell line, but not against the
HLA-A2 Melan-A Na 8 tumor cell line (Fig. 6 b).
Comparable results were obtained with Melan-A–specific
Figure 5. High frequency of
Melan-A–specific CD8 T cells in
CB and thymus. (a and b) Purified
CD8 T cells from 11 CB specimens
were stained with anti-CD3, anti-
CD8 mAbs, and A2/Melan-A (a), or
A2/Flu-MA (b) multimers. The per-
centage of A2/peptide multimer
cells is given in gated CD3CD8
lymphocytes. (c) Purified CB CD8
T cells were stained with A2/
Melan-A multimers, anti-CD3, anti-
CD8, and anti-CD45RA (left) or
anti-CCR7 (right) mAbs. Histo-
grams are shown for gated
CD3CD8A2/Melan-A cells and
are representative examples for seven
individuals. Gated A2/Melan-A
cells are painted in gray and negative
controls are in white. (d) Real time
PCR quantification of TRECs was
performed in whole CB CD8 T cells
and in Melan-A–specific T cells (0.08% of CD8 T cells) from CB15. TREC levels in CD8 T cells are representative for four individuals. (e and f) CD4-
depleted thymocytes from nine thymus specimens were stained with anti-CD3, anti-CD4, anti-CD8 mAbs, and A2/Melan-A (e) or A2/Flu-MA (f)
multimers. The percentage of A2/peptide multimer cells is given in CD3highCD4–CD8 thymocytes.
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T cells sorted from CB of newborns 07 and 08, and of
adults HD 008, HD 009, and HD 604 (unpublished data).
Thus, Melan-A–specific T cells already present in a high
frequency in the thymus have the capacity to efficiently
recognize endogenously produced Melan-A peptide(s).
Discussion
Although abundantly present in the mature T cell reper-
toire of HLA-A2 adult individuals, circulating Melan-A–
specific CD8 T cells display a naive phenotype (17–19). In
this study, we directly identified the origin of the large
Melan-A–specific T cell pool. First, high numbers of
Melan-A–specific T cells are already detected in CD8 SP
thymocytes and are maintained in the mature T cell reper-
toire of newborns and adults. Second, high TREC levels
and long telomeres are retained in circulating Melan-A–
specific T cells and are comparable with those found in
autologous-naive lymphocytes. Together, these results
demonstrate that the shaping of the preimmune T cell rep-
ertoire specific for the self-antigen Melan-A is mostly im-
posed by thymic output of a high frequency of precursors.
Thus, the size of the circulating Melan-A–specific T cell pool
in adults is at least 102 times larger than current estimates
for naive antigen-specific lymphocyte precursors, and ap-
proaches that of epitope-specific memory CD8 T cells.
Melan-A–specific thymocytes cannot be found in DP
cells, but become detectable in CD8 SP cells. The selective
detection of Melan-A–specific T cells in the latter subset
may be explained by at least two reasons. First, the lower
levels of TCR / molecules on DP thymocytes may not
be sufficient for efficient staining with MHC/peptide mul-
timers. Second, the frequency of Melan-A–specific thy-
mocytes is probably highly diluted in the DP stage by the

95% cells that will not reach the SP pool. Nonetheless,
our findings clearly show that a high frequency of Melan-
A–specific precursors is selected in the human thymus.
Once they have completed their thymic maturation, these
cells are seeded and maintained at high numbers in the pe-
ripheral blood (103 of circulating CD8 T cells), repre-
senting a total number of 0.5–2  106 cells. Because 98%
of all lymphocytes are sequestered in tissues (38), it is possi-
ble that 25100  106 cells recognizing the self-antigen
Melan-A persist in the peripheral lymphoid compartment.
In marked contrast, influenza-specific T cells are below de-
tection both in the thymus and in newborns, and only be-
come detectable in adult individuals, most likely driven by
extensive clonal expansion in response to viral infection.
The simplest explanation for the high frequency of cir-
culating Melan-A–specific CD8 T cells is peripheral ex-
pansion. This possibility, however, is ruled out by pa-
rameters reflecting the replicative history of circulating
Melan-A–specific T cells (TREC levels and telomere
length). The TREC levels in a naive T cell population at
any time will be determined by factors inclusive of thymic
production and T cell homeostasis (assuming no intracel-
lular TREC decay). As peripheral T cell division substan-
tially affects the intracellular TREC content (27), the
availability of TREC levels from thymocytes to mature
peripheral lymphocytes allows the calculation of the post-
thymic replicative history of CD8 T cells. If we first con-
sider CB, we may estimate that on average, CD8 T cells in
newborns (mean  SD, 24  5 TRECs in 100 cells) com-
pleted one to two population doublings relative to CD8
SP thymocytes (57  7 TRECs per 100 cells; unpublished
data). Such limited cell division may be controlled by con-
tinued specific recognition of self-peptide/MHC, respon-
sible for the persistence of mature lymphocytes in the pe-
riphery (5, 6). In peripheral blood of adults, CD8 T cells
include two groups with distinct replicative histories. Na-
ive (CCR7CD45RAhigh) CD8 T cells (7  3 TRECs
per 100 cells) completed approximately three population
doublings, whereas on average, memory/effector (non-
CCR7CD45RAhigh) CD8 T cells (0.5  0.4 TRECs per
100 cells) underwent seven population doublings in the
periphery. The strikingly different replicative histories of
CCR7CD45RAhigh and non-CCR7CD45RAhigh sub-
sets confirm that the combination of CCR7 and CD45RA
surface markers allows the distinction of naive from mem-
ory/effector lymphocytes. This conclusion is further sup-
ported by the finding that naive lymphocytes exhibit sig-
nificantly longer telomeres as compared with their
memory/effector counterparts. Furthermore, the relative
telomere length of naive lymphocytes is quite uniform, in-
dicating that these cells represent a homogeneous popula-
tion. If we now consider antigen-specific CD8 T cells,
Figure 6. Functional potential of
Melan-A–specific CD8 SP thy-
mocytes. (a) Purified Melan-A–spe-
cific CD8 SP thymocytes, which had
been expanded in vitro, were tested
in a 4-h 51Cr-release assay for their
cytolytic activity against A2 TAP-
deficient T2 cells in the presence of
exogenously added Melan-A26–35
(), Melan-A26–35 A27L analogue
(), or irrelevant influenza matrix58–66
peptides (). In lymphocyte to target cell ratio titrations (left), peptides were used at 1 	M. In peptide titrations (right), the lymphocyte to target cell ratio
used was 10:1. Results are representative examples for six Melan-A–specific T cell populations derived from thymus and peripheral blood of newborns
and adults. (b) Purified Melan-A–specific CD8 SP thymocytes, which had been expanded in vitro, were tested in a 4-h 51Cr-release assay for their cy-
tolytic activity against Me 290 (, A2 / Melan-A) and Na 8 (, A2 / Melan-A) tumor cells. Results are representative examples for six Melan-A–
specific T cell populations derived from thymus and peripheral blood of newborns and adults.
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Melan-A–specific T cells in CB (mean  SD, 14  4
TRECs per 100 cells) reveal a proliferative history com-
pared with that of the whole CD8 T cell pool. Likewise,
Melan-A–specific T cells in peripheral blood of adults
(5  2 TRECs per 100 cells) resemble the naive CD8 T
cell pool, as they also completed limited cell division. In-
deed, the data suggest that on average, Melan-A specific T
cells have only completed one cell division compared with
the autologous-naive subset (TREC dilution by 50%).
This may reflect a slightly increased division rate and/or
prolonged life span. In either case, the net effect would be
the observed consistently lower TREC content as com-
pared with the autologous naive CD8 T cells. Because all
Melan-A–specific T cells homogeneously retain long telo-
meres ex vivo, it also implies that most cells in the pool
underwent a similar number of divisions. In marked con-
trast to Melan-A–specific T cells, influenza-specific T cells
have an extensive replicative history in the periphery of
adults. Because their TRECs are not detectable, the virus-
specific T cells completed 
10 population doublings. In
this case a single thymocyte precursor may generate 
103
CD8 T cell progeny. This is in line with the recent finding
that after antigenic stimulation, naive CD8 T cells become
committed to dividing at least seven times and differentiat-
ing into memory/effector cells (39). In agreement with
these data, we observed significant telomere shortening of
influenza-specific T cells as compared with autologous-
naive CD8 T cells.
Accumulating evidence indicates a central role for self-
peptides in thymic selection. Interestingly, previous experi-
ments showed that Melan-A mRNA is not detectable in
the thymus, which suggests that the large Melan-A–specific
T cell pool might be shaped in the absence of the selecting
and/or deleting ligand (12). In this respect, it is noteworthy
that the Melan-A peptide sequence, recognized by CD8 T
cells from HLA-A2 individuals, is localized in the putative
hydrophobic transmembrane domain of the protein, which
greatly limits the diversity of its amino acid composition.
Indeed, sequence homology between the Melan-A peptide
and a broad range of self-derived proteins has recently been
reported (40, 41). Consequently, recognition of Melan-A–
cross-reactive ligands may play an important role in posi-
tive thymic selection by generating a large naive T cell
pool. Based on previous experimental work (42), we hy-
pothesize that highly specific interactions between self-
peptides and TCR, rather than promiscuous recognition,
are driving the positive selection process. However, since
there is increasing evidence that a wide variety of tissue-
specific antigens may be weakly expressed intrathymically
(43), we cannot exclude the possibility that weak expres-
sion of Melan-A in the thymus may also result in the dele-
tion of high-avidity CD8 T cells (3, 4, 10). It will be im-
portant to determine which sequence motifs are involved
in positive thymic selection of Melan-A–specific T cells.
Preliminary experiments seem to indicate that generation
of the large Melan-A–specific T cell pool is not due to se-
lection of a particular TCR. Indeed, we investigated the
TCR- repertoire of Melan-A–specific CD8 T cells ex
vivo in HD 009 by using multimers in conjunction with
anti-CD8 and anti–TCR- chain variable (BV) mAbs.
This analysis revealed that at least 13 out of 18 BV seg-
ments investigated were used (BV1, 2, 3, 7, 8, 13.1, 13.6,
14, 16, 17, 20, 21, 22), each representing 2–10% of the
whole Melan-A–specific repertoire (unpublished data). It is
noteworthy that analysis of complementary determining
region-3 length, and sequence of activated Melan-A–spe-
cific cells in tumor-infiltrated lymph nodes from melanoma
patients, indicated that these cells display a large and highly
diverse TCR- repertoire (44).
The mechanisms preventing the activation of circulating
Melan-A–specific CD8 T cells are unknown. It is conceiv-
able that the lack of peripheral activation reflects ignorance
(45, 46). Indeed, expression of Melan-A is restricted to cells
of the melanocytic lineage, including subepidermal mela-
nocytes, retinal pigmented epithelial cells, and choroidal
melanocytes, which are physiologically concealed from the
immune system. In addition, skin melanocytes are only
5% of the total skin cell pool, and thus there is a relatively
low abundance of the Melan-A antigen. Both spatial segre-
gation and low levels of Melan-A might explain why the
circulating Melan-A–specific T cell pool is virtually never
activated, despite frequent skin injury during the lifetime of
adults, and thus remains ignorant. In marked contrast,
Melan-A–specific T cells can be activated in patients with
malignant melanoma or rare autoimmune disorders. The
vast majority of melanoma patients contains detectable ac-
cumulations of memory/effector Melan-A–specific T cells
in metastatic tumor lesions (Fig. 4 [15, 47]). Thus, in the
appropriate milieu, including a high antigen load and dis-
ruption of tissue architecture brought about by tumor pro-
gression, Melan-A–specific T cells successfully overcome
ignorance and undergo clonal expansion. As documented
here, the emergence of memory/effector lymphocytes in
the Melan-A– specific T cell pool of melanoma patients is
accompanied by TREC dilution and telomere shortening.
It has also been suggested that Melan-A–specific T cells
may destroy melanocytes in the eyes of patients with Vogt-
Koyanagi-Harada disease and sympathetic ophthalmia,
which are systemic inflammatory disorders that affect tissues
containing melanocytes (48). Finally, the observation of an
elevated frequency of Melan-A–specific T cells in vitiligo
patients also underlines the involvement of these cells in
autoimmune destruction of skin melanocytes (49, 50).
The key finding in this study is that a large pool of hu-
man-naive CD8 T lymphocytes specific for the self-antigen
Melan-A can be identified and characterized by multimer
staining in the thymus and peripheral lymphoid compart-
ment of healthy individuals. Our results provide direct evi-
dence that this T cell pool is generated by thymic output of
a high frequency of precursors that undergo limited cell di-
vision in the periphery. It will be of great interest to iden-
tify the ligands involved in selecting and maintaining such
an abundant self-specific naive T cell repertoire.
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